Wearable Injectors Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Wearable Injectors Market by Type of Device, Type of Degree of Automation, Type of Usability, Type of Therapeutic Area, and Geographical Regions – Trends and Forecast Till 2035
報告摘要
WEARABLE INJECTORS MARKET: OVERVIEW
As per Roots Analysis, the global wearable injectors market is estimated to grow from USD 6.5 billion in the current year to USD 13.0 billion by 2035, at a CAGR of 7.4% during the forecast period, till 2035.
Wearable Injectors Market: Growth and Trends
Wearable injectors, also known as on-body patch pumps, are skin-adhered devices designed to deliver large-volume or high-viscosity drugs subcutaneously over extended durations, ranging from minutes to several hours. These injectors enable patients to self-administer complex biologics and chronic disease therapies outside clinical settings, eliminating the need for frequent clinical visits. Given the growing prevalence of chronic disorders, including diabetes, cancer, rheumatoid arthritis, and cardiovascular conditions, healthcare systems continue to witness immense pressure amid an aging population.
As per the report of Centers for Disease Control and Prevention, nearly 1.9 million people are diagnosed with Cancer in the US, and the cost of care is estimated to reach over USD 230 billion by 2030. Moreover, more than 8,50,000 died due to heart stroke in 2024 and the cost of managing cardiovascular diseases is projected to reach nearly USD 2 trillion by 2050. Chronic disease management requires frequent visits to hospitals which not only increase treatment costs but also reduce patient’s adherence to treatment.
To address this burden, pharmaceutical and medical device companies are increasingly investing in patient-centric drug delivery innovations that improve treatment adherence and clinical outcomes at home. Wearable injectors simplify the administration of sustained basal, bolus, or continuous doses of high-volume biologics, while built-in safety features reduce needlestick injuries and improve patient confidence for home use. This shift is exemplified by recent developments such as BD's pharma-sponsored combination product trial using the BD Libertas wearable injector for subcutaneous delivery of complex biologics, reflecting growing industry confidence in large-volume, patient-ready delivery systems.
Wearable devices have gained wide acceptance for subcutaneous drug administration in home-care settings. This shift toward self-administration has pushed device developers and pharmaceutical companies to add advanced features to their offerings. These advanced features include AI-based algorithms, companion mobile apps, smart health monitoring, dosing reminders, and audible or visual delivery confirmation. Continuous innovation in drug delivery devices, along with growing acceptance of wearable injectors, is expected to support steady market growth over the forecast period.
Growth Drivers: Strategic Enablers of Market Expansion
The wearable injectors market is experiencing robust growth, driven by the increasing prevalence of chronic diseases, including diabetes, cancer, rheumatoid arthritis, and cardiovascular disorders, alongside a growing geriatric population. Rising demand for long-term, precise drug administration is accelerating the adoption of wearable drug delivery systems that improve treatment adherence and therapeutic outcomes. The expanding use of biologics and the shift toward patient-centric healthcare are further supporting market growth. Additionally, the increasing preference for self-administration and home-based care is driving the adoption of wearable patch and infusion injectors, reducing reliance on healthcare facilities while enhancing patient convenience. Advancements in digital health technologies, such as Bluetooth and Wi-Fi connectivity, AI-enabled dose management, smartphone integration, and remote patient monitoring, are further improving device functionality and enabling personalized, connected healthcare, thereby strengthening the long-term growth prospects of the wearable injectors market.
Market Challenges: Critical Barriers Impeding Progress
Despite its strong growth prospects, the wearable injectors market faces several challenges that may limit broader adoption. High device costs, driven by advanced technologies and specialized materials, remain a significant barrier, particularly in regions with limited reimbursement support and high out-of-pocket healthcare expenses. Additionally, stringent regulatory requirements and lengthy approval processes increase development costs and delay product commercialization. Limited awareness and inadequate training among patients and healthcare professionals further increase the risk of improper device usage and suboptimal treatment outcomes, especially in elderly populations and resource-constrained settings. Addressing these cost, reimbursement, regulatory, and educational challenges will be critical to accelerating market adoption and realizing the full commercial potential of wearable injector technologies.
Wearable Injectors Market: Key Insights
The report delves into the current state of the wearable injectors market and identifies potential growth opportunities within the industry. Some key findings include:
• Device manufacturers in the wearable injectors market predominantly rely on direct sales to reach hospitals, pharmaceutical companies, and specialty channels. This model currently limits the visibility that third-party distributors have into wearable injector commercialization, despite their established reach into home care and retail pharmacy networks.
• Specialty pharmacies and third-party logistics (3PL) providers are emerging as the primary distribution intermediaries for wearable injector-based biologic therapies, rather than traditional pharmaceutical wholesalers. McKesson Plasma and Biologics illustrates this shift, offering dedicated specialty distribution and cold chain services tailored to biologics and other high-touch drug categories.
• Distributors seeking entry into the wearable injectors market must demonstrate specialized cold chain and handling infrastructure. Cardinal Health's 3PL Services unit reflects this requirement, having built dedicated capabilities for temperature-controlled storage and transport of biologics and injectable therapies.
• Direct-to-patient and home delivery models, integrated with telehealth and e-prescribing, are reshaping the distributor value proposition from pure product movement toward end-to-end patient onboarding, device training, and adherence support.
• Accreditation from bodies such as URAC and the Accreditation Commission for Health Care (ACHC) is increasingly required for distributors and specialty pharmacies seeking inclusion in limited-distribution networks for wearable injector-paired biologics.
• Rising demand for self-injection systems, driven in part by GLP-1 receptor agonist therapies, is prompting contract development and manufacturing organizations to integrate device assembly and distribution capabilities directly into their service offerings, blurring the boundary between manufacturing and distribution partners.
• Regulatory reform of pharmacy benefit managers, including the Consolidated Appropriations Act of 2026 mandating rebate pass-through and pricing transparency, is altering the economics of specialty distribution in the US and encouraging manufacturers to diversify beyond PBM-affiliated pharmacies.
• Distributors handling wearable injectors increasingly compete on value-added services such as patient hub support, device training, and connected app enablement, rather than on logistics efficiency alone, mirroring a shift already observed across the broader specialty biologics distribution market.
• Consolidation among large-scale specialty distributors and 3PLs is raising barriers to entry for smaller regional players. At the same time, the shift toward decentralized, home-based biologic administration is creating openings for niche distributors with condition-specific or region-specific expertise.
Wearable Injectors Market
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Device
• Patch Pumps
• Infusion Pumps
By Degree of Automation
• Automated / Smart Pumps
• Manual Pumps
By Usability
• Disposable
• Reusable (Disposable Components)
By Therapeutic Area
• Oncological Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Neurological Disorders
• Other Disorders
By Geographical Regions
• North America
• US
• Canada
• Mexico
• Europe
• France
• Germany
• UK
• Italy
• Spain
• Rest of Europe
• Asia
• China
• India
• Japan
• Rest of Asia
• Middle East and North Africa
• Egypt
• Israel
• Saudi Arabia
• Latin America
• Argentina
• Brazil
Wearable Injectors Market: Key Segments
Infusion Pumps Continue to Lead the Wearable Injectors Market
Based on our market assessment, infusion pumps currently constitute the largest segment of the insulin wearable injectors market, accounting for approximately 95% of the overall market share. The segment is expected to retain its dominant position throughout the forecast period, primarily due to the high level of dosing precision, programmable drug delivery capabilities, and proven clinical effectiveness offered by these devices. Their widespread adoption across insulin-dependent patient populations, coupled with established reimbursement pathways and strong physician confidence, continues to reinforce their market leadership.
In contrast, the patch pumps segment is anticipated to register the fastest growth rate over the forecast period. This growth is driven by the increasing demand for patient-centric drug delivery solutions that enable convenient, discreet, and hands-free self-administration in home-care settings. Their compact, skin-adhered design enhances patient mobility, improves treatment adherence, and aligns with the broader industry shift toward decentralized healthcare and remote disease management, particularly for chronic conditions such as diabetes and oncology.
North America Maintains Market Leadership
According to our market projections, North America is expected to maintain its leadership in the wearable injectors market through 2035, accounting for nearly 70% of the global market share. The region's dominance is underpinned by a well-established healthcare infrastructure, a high prevalence of diabetes and other chronic diseases, favorable reimbursement frameworks, and the early adoption of advanced drug delivery technologies. Furthermore, strong healthcare expenditure, a supportive regulatory environment for innovative medical devices, and the presence of leading wearable injector manufacturers continue to reinforce the region's competitive position. Increasing integration of digital health solutions and growing patient preference for home-based disease management are also expected to sustain long-term market growth across North America.
Asia-Pacific Emerges as the Fastest-Growing Regional Market
According to our market projections, the Asia-Pacific’s wearable injectors market is expected to register the highest CAGR during the forecast period, positioning the region as the fastest-growing market globally. This robust growth is being driven by rapid urbanization, expanding middle-class populations, rising disposable incomes, and the increasing prevalence of chronic diseases across major economies such as China and India.
In addition, demographic shifts, particularly the growing geriatric population, are creating sustained demand for convenient, home-based drug delivery solutions. Government initiatives aimed at strengthening healthcare infrastructure, expanding insurance coverage, promoting domestic medical device manufacturing, and improving access to advanced healthcare technologies are further accelerating market expansion. The increasing penetration of biologics, coupled with rising awareness of self-administration therapies and the adoption of digital health solutions, is also expected to support long-term market growth across the region.
Oncological Disorders Account for the Largest Share of the Non-Insulin Segment
Based on our analysis, the oncological disorders segment currently accounts for the largest share of the non-insulin wearable injectors market and is expected to maintain its market leadership throughout the forecast period. This dominance is primarily driven by the increasing global incidence of cancer, the expanding adoption of biologics and monoclonal antibody therapies, and the growing preference for subcutaneous administration of high-volume therapeutics. Wearable injectors are particularly well suited for oncology applications, as they enable the controlled and prolonged delivery of complex drug formulations, improve patient comfort, reduce infusion chair time, and facilitate the transition of cancer treatment from hospital settings to home-based care.
Example Players in Wearable Injectors Market
• Becton Dickinson (BD)
• Enable Injections
• Insulet
• Medtronic
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed
Expert Interview and Industry Insights
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Mid-Sized Company, US
• Chief Executive Officer, Small Company, Denmark
• Former President and Chief Executive Officer, Mid-Sized Company, US
• Vice President and Chief Scientist, Large Company, Israel
• Former Vice President and General Manager, Biologics, Very Large Company, US
• Anonymous, Large Company, Switzerland
• Engineering Project Manager / Senior System Engineer, Small Company, Switzerland
• Vice President, Marketing and Alliance Management, Mid-Sized Company, US
WEARABLE INJECTORS MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the wearable injectors market, focusing on key market segments, including type of device, degree of automation, usability, therapeutic area, and geographical regions.
• Insulin Wearable Injectors Landscape: A detailed assessment of the overall insulin wearable injectors market landscape, featuring information on several relevant parameters, such as type of device, degree of automation, compatibility with high-viscosity drugs, and regulatory approvals. Additionally, it features detailed analysis of device manufacturers, based on parameters such as year of establishment, company size (based on employee count), and location of headquarters.
• Non-Insulin Wearable Injectors Landscape: A detailed assessment of the overall non-insulin wearable injectors market landscape, featuring information on parameters such as usability, therapeutic area, drug compatibility, and status of development. Additionally, it features detailed analysis of device developers, based on parameters such as year of establishment, company size, and location of headquarters.
• Company Profiles: In-depth profiles of prominent players engaged in offering wearable injectors, featuring information on their year of establishment, location of headquarters, company size (in terms of number of employees), management team, portfolio, and key initiatives.
• Patent Analysis: An analysis of the patents filed / granted related to wearable injector devices, based on parameters such as type of patent, patent application year, patent publication year, patent jurisdiction, CPC symbols, type of applicant, patent benchmarking, and patent valuation.
• Recent Developments: A detailed analysis of the various recent developments in this industry, including partnerships and collaborations, funding and investments, and global events, based on several relevant parameters.
• Porter's Five Forces Analysis: A qualitative analysis of five competitive forces in this domain, namely, threats of new entrants, bargaining power of buyers, bargaining power of providers, threat of substitute products, and rivalry among existing competitors.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
KEY QUESTIONS ANSWERED IN THIS REPORT
• Which are the leading companies in the wearable injectors market?
• Which region dominates the wearable injectors market?
• What are the key trends observed in the wearable injectors market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by wearable injector developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.
ADDITIONAL BENEFITS
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated Report if the Report is 6-12 Months Old or Older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.4. Project Methodology
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.3. Market Assessment Framework
3.4. Forecasting Tools and Techniques
3.5. Key Considerations
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.2. Currency Coverage
4.2.3. Foreign Currency Exchange Rate
4.2.4. Recession
4.2.5. Inflation
4.2.6. Interest Rates
4.2.7. Commodity Flow Analysis
4.2.8. Global Trade Dynamics
4.2.9. War Impact Analysis
4.2.10. COVID Impact / Related Factors
4.2.11. Other Indicators
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Introduction to Drug Delivery Devices
6.3. Conventional Parenteral Drug Delivery Devices
6.3.1. Needlestick Injuries
6.3.2. Incidence and Cost Burden
6.3.3. Prevention of Needlestick Injuries
6.3.4. Government Legislations for the Prevention of Needlestick Injuries
6.4. Emergence of Self-Administration Devices
6.4.1. Key Driving Factors
6.4.1.1. Rising Burden of Chronic Diseases
6.4.1.2. Healthcare Cost Savings
6.4.1.3. Need for Immediate Treatment in Emergency Situations
6.4.1.4. Growing Injectable Drugs Market
6.4.1.5. Need for Improving Medication Adherence
6.5. Available Self-Injection Devices
6.5.1. Prefilled Syringes
6.5.2. Pen-Injectors
6.5.3. Needle-Free Injectors
6.5.4. Autoinjectors
6.5.5. Wearable Injectors
6.6. Regulatory Considerations
6.6.1. Medical Devices
6.6.2. Drug Device Combination Products
6.7. Future Perspectives
7. WEARABLE INJECTORS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
7.2.1. Analysis by Type of Device
7.2.2. Analysis by Status of Development
7.2.3. Analysis by Type of Drug Delivery
7.2.4. Analysis by Usability
7.2.5. Analysis by Drug Reservoir Volume
7.2.6. Analysis by Type of Drug Molecule
7.2.7. Analysis by Type of Dose
7.2.8. Analysis by Dose of Drug
7.2.9. Analysis by Mode of Injection
7.2.10. Analysis by Therapeutic Area
7.2.11. Analysis by Type of Drug Container
7.2.12. Analysis by Mode of Drug Filling
7.3. Wearable Injectors for Non-Insulin Drugs: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Non-Insulin
8. DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
8.2.1. Analysis by Type of Device
8.2.2. Analysis by Status of Development
8.2.3. Analysis by Type of Drug Delivery
8.2.4. Analysis by Usability
8.2.5. Analysis by Drug Reservoir Volume
8.2.6. Analysis by Type of Drug Molecule
8.2.7. Analysis by Type of Dose
8.2.8. Analysis by Dose of Drug
8.2.9. Analysis by Mode of Injection
8.2.10. Analysis by Therapeutic Area
8.2.11. Analysis by Type of Drug Container
8.2.12. Analysis by Mode of Drug Filling
8.3. Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Device Developers: Distribution by Number of Drug Device Combination Developed
9. WEARABLE INJECTORS FOR INSULIN: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Wearable Injectors for Insulin: Overall Market Landscape
9.2.1. Analysis by Type of Device
9.2.2. Analysis by Status of Development
9.2.3. Analysis by Type of Insulin Delivery
9.2.4. Analysis by Type of Automated Insulin Delivery
9.2.5. Analysis by Type of Connectivity Feature
9.2.6. Analysis by Type of Feedback Mechanism
9.2.7. Analysis by Waterproofing Capability
9.2.8. Analysis by Usability
9.2.9. Analysis by Period of Use
9.2.10. Analysis by Type of Advanced Feature
9.2.11. Analysis by Type of Drug Container
9.2.12. Analysis by Mode of Drug Filling
9.2.13. Analysis by Type of Dose
9.2.14. Analysis by Type of Diabetes
9.2.15. Analysis by Availability of Connectivity Feature
9.3. Wearable Injectors for Insulin: Developer Landscape
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Leading Players: Analysis by Number of Wearable Injectors Developed for Insulin
10. PRODUCT COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Methodology
10.4. Product Competitiveness Analysis
10.4.1. Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
10.4.2. Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
10.4.3. Product Competitiveness Analysis: Wearable Injectors for Insulin
11. WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES
11.1. Chapter Overview
11.2. Key Players Developing Wearable Injectors for Non-Insulin
11.2.1. CCBio
11.2.1.1. Company Overview
11.2.1.2. Product Portfolio
11.2.1.3. Recent Developments and Future Outlook
11.2.2. E3D Elcam Drug Delivery Devices
11.2.3. Enable Injections
11.2.4. Gerresheimer
11.2.5. Sonceboz
11.2.6. Weibel CDS (Acquired by SHL Medical)
11.2.7. West Pharmaceuticals
11.3. Key Players Developing Wearable Injectors for Insulin
11.3.1. CeQur
11.3.2. Debiotech
11.3.3. Eli Lilly
11.3.4. Insulet
11.3.5. Medtronic
11.3.6. Medtrum Technologies
11.3.7. PharmaSens
11.3.8. Roche
11.3.9. SOOIL Development
12. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES
12.1. Chapter Overview
12.2. Neulasta® (pegfilgrastim) OnPro™ Kit
12.3. D-mine® Pump
12.4. Lasix® ONYU
12.5. The LUTREPULSE® System
12.6. ND0612L Next generation patch pump
12.7. Unnamed (Developed by Phillips Medisize)
12.8. FUROSCIX®
12.9. SMT-201 Pump
12.10. SMT-301 Pump
12.11. ULTOMRIS® Smartdose Injector (ravulizumab-cwvz)
12.12. EMPAVELI® Injector
12.13. SKYRIZI® On Body Injector (risankizumab)
12.14. VYALEV™ Pump (foscarbidopa and foslevodopa)
12.15. UDENYCA® on-body injector
12.16. ONAPGO™
12.17. Remunity® Pump
12.18. G-Lasta® BodyPod
12.19. Sarclisa (isatuximab) On-Body Injector
13. PARTNERSHIPS AND COLLABORATIONS
14. KEY ACQUISITION TARGETS
15. PATENT ANALYSIS
16. WEARABLE INJECTORS: LIKELY DRUG CANDIDATES
16.1. Chapter Overview
16.2. Marketed Drugs
16.2.1. Most Likely Candidates for Delivery via Wearable Injectors
16.2.2. Likely Candidates for Delivery via Wearable Injectors
16.2.3. Less Likely Candidates for Delivery via Wearable Injectors
16.2.4. Least Likely Candidates for Delivery via Wearable Injectors
16.3. Clinical Stage Drugs
16.3.1. Most Likely Candidates for Delivery via Wearable Injectors
16.3.2. Likely Candidates for Delivery via Wearable Injectors
16.3.3. Less Likely Candidates for Delivery via Wearable Injectors
16.3.4. Least Likely Candidates for Delivery via Wearable Injectors
17. CLINICAL TRIAL ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Wearable Injectors: Clinical Trial Analysis
17.3.1. Analysis by Trial Recruitment Status
17.3.2. Analysis by Trial Registration Year
17.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
17.3.4. Analysis by Trial Phase
17.3.5. Analysis of Enrolled Patient Population by Trial Phase
17.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
17.3.7. Analysis by Study Design
17.3.8. Analysis by Type of Sponsor / Collaborator
17.3.9. Analysis by Therapeutic Area
17.3.10. Most Active Players: Analysis by Number of Registered Trials
17.3.11. Most Popular Wearable Injectors: Analysis by Number of Registered Trials
17.3.12. Analysis by Geography
17.3.12.1. Analysis by Trial Recruitment Status and Geography
17.3.12.2. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography
18. FUNDING AND INVESTMENT ANALYSIS
18.1. Chapter Overview
18.2. Types of Funding
18.3. Wearable Injectors: Funding and Investment Analysis
18.3.1. Analysis by Year of Funding
18.3.2. Analysis of Amount Invested by Year
18.3.3. Analysis by Type of Funding
18.3.4. Analysis by Type of Device
18.3.5. Analysis of Amount Invested by Year and Type of Funding
18.3.6. Analysis of Amount Invested by Type of Device
18.3.7. Analysis by Target Disease Indication
18.3.8. Most Active Players: Analysis by Number of Funding Instances
18.3.9. Most Active Players: Analysis by Amount Invested
18.3.10. Leading Investors: Analysis by Number of Funding Instances
18.3.11. Analysis by Geography
19. SWOT ANALYSIS
19.1. Chapter Overview
19.2. SWOT Analysis
19.2.1. Strengths
19.2.2. Weaknesses
19.2.3. Opportunities
19.2.4. Threats
19.3. Wearable Injectors: Future Growth Opportunities
19.3.1. Rising Focus on Self-Administration of Drugs
19.3.2. Possibility of Integration with Mobile Applications
19.3.3. Potential Life Cycle Management Tool
19.3.4. Potential Usability for Multiple Therapeutic Areas
20. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN
20.1. Chapter Overview
20.2. Device Development Supply Chain
20.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
20.4. List of CMOs
20.4.1. Geographical Distribution of CMOs
20.5. Medical Devices Design and Development Service Providers
21. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
21.1. Chapter Overview
21.2. General Regulatory and Reimbursement Guidelines for Medical Devices
21.3. Regulatory and Reimbursement Landscape in North America
21.3.1. The US Scenario
21.3.1.1. Regulatory Authority
21.3.1.2. Review / Approval Process
21.3.1.3. Reimbursement Landscape
21.3.1.3.1. Payer Mix
21.3.1.3.2. Reimbursement Process
21.3.2. The Canadian Scenario
21.3.2.1. Regulatory Authority
21.3.2.2. Review / Approval Process
21.3.2.3. Reimbursement Landscape
21.3.2.3.1. Payer Mix
21.3.2.3.2. Reimbursement Process
21.3.3. The Mexican Scenario
21.3.3.1. Regulatory Authority
21.3.3.2. Review / Approval Process
21.3.3.3. Reimbursement Landscape
21.3.3.3.1. Payer Mix
21.4. Regulatory and Reimbursement Landscape in Europe
21.4.1. Overall Scenario
21.4.1.1. Overall Regulatory Authority
21.4.1.2. Overall Review / Approval Process
21.4.2. The UK Scenario
21.4.2.1. Regulatory Authority
21.4.2.2. Review / Approval Process
21.4.2.3. Reimbursement Landscape
21.4.2.3.1. Payer Mix
21.4.2.3.2. Reimbursement Process
21.4.3. The French Scenario
21.4.3.1. Regulatory Authority
21.4.3.2. Review / Approval Process
21.4.3.3. Reimbursement Landscape
21.4.3.3.1. Payer Mix
21.4.3.3.2. Reimbursement Process
21.4.4. The German Scenario
21.4.4.1. Regulatory Authority
21.4.4.2. Review / Approval Process
21.4.4.3. Reimbursement Landscape
21.4.4.3.1. Payer Mix
21.4.4.3.2. Reimbursement Process
21.4.5. The Italian Scenario
21.4.5.1. Regulatory Authority
21.4.5.2. Review / Approval Process
21.4.5.3. Reimbursement Landscape
21.4.5.3.1. Payer Mix
21.4.5.3.2. Reimbursement Process
21.4.6. The Spanish Scenario
21.4.6.1. Regulatory Authority
21.4.6.2. Review / Approval Process
21.4.6.3. Reimbursement Landscape
21.4.6.3.1. Payer Mix
21.4.6.3.2. Reimbursement Process
21.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
21.5.1. The Australian Scenario
21.5.1.1. Regulatory Authority
21.5.1.2. Review / Approval Process
21.5.1.3. Reimbursement Landscape
21.5.1.3.1. Payer Mix
21.5.1.3.2. Reimbursement Process
21.5.2. The Brazilian Scenario
21.5.2.1. Regulatory Authority
21.5.2.2. Review / Approval Process
21.5.2.3. Reimbursement Landscape
21.5.2.3.1. Payer Mix
21.5.2.3.2. Reimbursement Process
21.5.3. The Chinese Scenario
21.5.3.1. Regulatory Authority
21.5.3.2. Review / Approval Process
21.5.3.3. Reimbursement Landscape
21.5.3.3.1. Payer Mix
21.5.3.3.2. Reimbursement Process
22. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
22.1. Chapter Overview
22.2. Market Drivers
22.3. Market Restraints
22.4. Market Opportunities
22.5. Market Challenges
22.6. Conclusion
23. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
23.3.1. Scenario Analysis
23.3.1.1. Conservative Scenario
23.3.1.2. Optimistic Scenario
23.4. Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
23.4.1. Scenario Analysis
23.4.1.1 Conservative Scenario
23.4.1.2. Optimistic Scenario
23.5. Key Market Segmentations
24. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY TYPE OF DEVICE
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
24.3.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
24.3.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
24.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
24.4.1. Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
24.4.2. Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
24.5. Data Triangulation and Validation
25. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY USABILITY
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
25.3.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
25.3.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
25.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
25.4.1. Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
25.4.2. Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
25.5. Data Triangulation and Validation
26. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY THERAPEUTIC AREA
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
26.3.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.3.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.3.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.3.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.3.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
26.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
26.4.1. Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.4.2. Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.4.3. Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.4.4. Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.4.5. Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
26.5. Data Triangulation and Validation
27. WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS, BY GEOGRAPHICAL REGIONS
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
27.3.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.3.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.3.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.3.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.3.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
27.4. Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
27.4.1. Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.4.2. Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.4.3. Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.4.4. Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.4.5. Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
27.5. Market Dynamics Assessment
27.5.1. Penetration Growth (P-G) Matrix
27.5.2. Market Movement Analysis
27.6. Data Triangulation and Validation
28. WEARABLE INJECTORS MARKET FOR INSULIN
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
28.3.1. Scenario Analysis
28.3.1.1. Conservative Scenario
28.3.1.2. Optimistic Scenario
28.4. Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
28.4.1. Scenario Analysis
28.4.1.1. Conservative Scenario
28.4.1.2. Optimistic Scenario
28.5. Key Market Segmentations
29. WEARABLE INJECTORS MARKET FOR INSULIN, BY TYPE OF DEVICE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
29.3.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
29.3.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
29.4. Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
29.4.1. Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
29.4.2. Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
29.5. Data Triangulation and Validation
30. WEARABLE INJECTORS MARKET FOR INSULIN, BY DEGREE OF AUTOMATION
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
30.3.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
30.3.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
30.4. Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
30.4.1. Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
30.4.2. Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
30.5. Data Triangulation and Validation
31. WEARABLE INJECTORS MARKET FOR INSULIN, BY GEOGRAPHICAL REGIONS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
31.3.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.3.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
31.4. Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
31.4.1. Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.1.1. Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.1.2. Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2. Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.1. Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.2. Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.3. Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.4. Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.5. Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.2.6. Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3. Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3.1. Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3.2. Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3.3. Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3.4. Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.3.5. Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.4. Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.4.1. Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.4.2. Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.4.3. Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.5. Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.5.1. Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.5.2. Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.4.5.3. Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
31.5. Market Dynamics Assessment
31.5.1. Penetration Growth (P-G) Matrix
31.5.2. Market Movement Analysis
31.6. Data Triangulation and Validation
32. CONCLUDING INSIGHTS
33. EXECUTIVE INSIGHTS
33.1. Chapter Overview
33.2. Company A
33.2.1. Company Snapshot
33.2.2. Interview Transcript: Chief Executive Officer
33.3. Company B
33.3.1. Company Snapshot
33.3.2. Interview Transcript: Chief Executive Officer
33.4. Company C
33.4.1. Company Snapshot
33.4.2. Interview Transcript: Chief Executive Officer
33.5. Company D
33.5.1. Company Snapshot
33.5.2. Interview Transcript: Former President and Chief Executive Officer
33.6. Company E
33.6.1. Company Snapshot
33.6.2. Interview Transcript: Vice President and Chief Scientist
33.7. Company F
33.7.1. Company Snapshot
33.7.2. Interview Transcript: Former Vice President and General Manager, Biologics
33.8. Company G
33.8.1. Company Snapshot
33.8.2. Interview Transcript: Anonymous
33.9. Company H
33.9.1. Company Snapshot
33.9.2. Interview Transcript: Engineering Project Manager / Senior System Engineer
33.10. Company I
33.10.1. Company Snapshot
33.10.2. Interview Transcript: Vice President, Marketing and Alliance Management
34. APPENDIX I: TABULATED DATA
35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 7.1 Wearable Injectors for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 7.2 Wearable Injectors for Non-Insulin Drugs: Information on Type of Dose, Type of Drug Container and Mode of Drug Filling
Table 7.3 Wearable Injectors for Non-Insulin Drugs: Information on Container Volume, Route of Administration and Mode of Injection
Table 7.4 Wearable Injectors for Non-Insulin Drugs: Information on Mechanism of Action / Driving Force and Type of Technology
Table 7.5 Wearable Injectors for Non-Insulin Drugs: Information on Availability of Connectivity Feature and Type of Compatible Drug
Table 7.6 Wearable Injectors for Non-Insulin Drugs: Information on Compatibility with High Viscosity Drugs and Therapeutic Area
Table 7.7 Wearable Injectors for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 8.1 Drug Device Combinations for Non-Insulin Drugs: Information on Status of Development, Type of Device and Usability
Table 8.2 Drug Device Combinations for Non-Insulin Drugs: Information on Type of Dose, Mode of Drug Filling, Type of Drug Container and Container Volume
Table 8.3 Drug Device Combinations for Non-Insulin Drugs: Information on Route of Administration, Mode of Injection and Type of Compatible Drug
Table 8.4 Drug Device Combinations for Non-Insulin Drugs: Information on Drug Delivery Technology, Mechanism of Action / Driving Force and Therapeutic Area
Table 8.5 Drug Device Combinations for Non-Insulin Drugs: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 9.1 Wearable Injectors for Insulin: Information on Status of Development, Type of Device and Type of Insulin Delivery
Table 9.2 Wearable Injectors for Insulin: Information on Type of Automated Insulin Delivery, Type of Connectivity Feature and Type of Feedback Mechanism
Table 9.3 Wearable Injectors for Insulin: Information on Waterproofing Capability, Usability and Period of Use
Table 9.4 Wearable Injectors for Insulin: Information on Type of Advanced Feature, Type of Drug Container and Mode of Drug Filling
Table 9.5 Wearable Injectors for Insulin: Information on Type of Dose, Type of Diabetes and Availability of Connectivity Feature
Table 9.6 Wearable Injectors for Insulin: Information on Device Developer, Year of Establishment, Company Size, and Location of Headquarters
Table 11.1 Wearable Injector Developers: List of Companies Profiled
Table 11.2 CCBio: Company Overview
Table 11.3 CCBio: Device Portfolio
Table 11.4 CCBio: Recent Developments and Future Outlook
Table 11.5 E3D Elcam Drug Delivery Device: Company Overview
Table 11.6 E3D Elcam Drug Delivery Device: Device Portfolio
Table 11.7 E3D Elcam Drug Delivery Devices: Recent Developments and Future Outlook
Table 11.8 Enable Injections: Company Overview
Table 11.9 Enable Injections: Device Portfolio
Table 11.10 Enable Injections: Recent Developments and Future Outlook
Table 11.11 Gerresheimer: Company Overview
Table 11.12 Gerresheimer: Device Portfolio
Table 11.13 Gerresheimer: Recent Developments and Future Outlook
Table 11.14 Sonceboz: Company Overview
Table 11.15 Sonceboz: Device Portfolio
Table 11.16 Sonceboz: Recent Developments and Future Outlook
Table 11.17 Weibel CDS: Company Overview
Table 11.18 Weibel CDS: Device Portfolio
Table 11.19 Weibel CDS: Developments and Future Outlook
Table 11.20 West Pharmaceuticals: Company Overview
Table 11.21 West Pharmaceuticals: Device Portfolio
Table 11.22 West Pharmaceuticals: Developments and Future Outlook
Table 11.23 CeQur: Company Overview
Table 11.24 CeQur: Device Portfolio
Table 11.25 CeQur: Developments and Future Outlook
Table 11.26 Eli Lilly: Company Overview
Table 11.27 Eli Lilly: Device Portfolio
Table 11.28 Eli Lilly: Developments and Future Outlook
Table 11.29 Insulet: Company Overview
Table 11.30 Insulet: Device Portfolio
Table 11.31 Insulet: Developments and Future Outlook
Table 11.32 Medtronic: Company Overview
Table 11.33 Medtronic: Device Portfolio
Table 11.34 Medtronic: Developments and Future Outlook
Table 11.35 Medtrum Technologies: Company Overview
Table 11.36 Medtrum Technologies: Device Portfolio
Table 11.37 Medtrum Technologies: Developments and Future Outlook
Table 11.38 Roche: Company Overview
Table 11.39 Roche: Device Portfolio
Table 11.40 Roche: Developments and Future Outlook
Table 11.41 SOOIL Development: Company Overview
Table 11.42 SOOIL Development: Device Portfolio
Table 11.43 SOOIL Development: Developments and Future Outlook
Table 12.1 Drug Device Combination: 3 mL Micropump (Furosemide)
Table 12.2 Drug Device Combination: 3M hMTS (Adalimumab)
Table 12.3 Drug Device Combination: D-mine Pump (Apomorphine)
Table 12.4 Drug Device Combination: On-body Infusor (Furosemide)
Table 12.5 Drug Device Combination: Herceptin SC Injector (Herceptin)
Table 12.6 Drug Device Combination: ND0712H Belt Pump (Levodopa / Carbidopa)
Table 12.7 Drug Device Combination: ND0712L belt pump (Levodopa / Carbidopa)
Table 12.8 Drug Device Combination: ND0712L next generation patch pump (Levodopa / Carbidopa)
Table 12.9 Drug Device Combination: ND0801 (Apomorphine)
Table 12.10 Drug Device Combination: ND0901 (Levodopa / Carbidopa)
Table 12.11 Drug Device Combination: Neulasta Onpro On-Body Injector (Neulasta)
Table 12.12 Drug Device Combination: Pushtronex System (Repatha)
Table 12.13 Drug Device Combination: SMT-201 (Ketorolac)
Table 12.14 Drug Device Combination: SMT-301 (Bupivacaine)
Table 12.15 Drug Device Combination: The LUTREPULSE System (Lutrepulse)
Table 12.16 Drug Device Combination: Trevyent (Treprostinil)
Table 12.17 Drug Device Combination: Ultomris (Ravulizumab)
Table 13.1 Wearable Injectors: List of Partnerships and Collaborations, 2018-2021
Table 14.1 Wearable Injectors: List of Key Acquisitions, 2000-2023
Table 14.2 Non-Insulin Drug Delivery Devices: Likelihood of Players for Acquisition
Table 14.3 Insulin Delivery Devices: Likelihood of Players for Acquisition
Table 15.1 Patent Analysis: Prominent CPC Symbols
Table 15.2 Patent Analysis: List of Top CPC Symbols
Table 15.3 Patent Analysis: Most Popular CPC Symbols
Table 15.4 Patent Analysis: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 16.1 Marketed Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.2 Marketed Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.3 Marketed Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.4 Marketed Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 16.5 Clinical Stage Drugs: Most Likely Candidates for Delivery via Wearable Injectors
Table 16.6 Clinical Stage Drugs: Likely Candidates for Delivery via Wearable Injectors
Table 16.7 Clinical Stage Drugs: Less Likely Candidates for Delivery via Wearable Injectors
Table 16.8 Clinical Stage Drugs: Least Likely Candidates for Delivery via Wearable Injectors
Table 18.1 List of Funding Instances: Information on Company, Year of Funding, Type, Amount Invested and Investors
Table 20.1 List of Contract Manufacturing Organizations
Table 20.2 List of Medical Device Product Design and Development Companies
Table 21.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 21.2 Device Classification: US
Table 21.3 Device Classification: Canada
Table 21.4 Data Requirements and Characteristics of Province-wide HTA Processes in Canada
Table 21.5 Device Classification: Mexico
Table 21.6 Device Classification: Europe
Table 21.7 List of CE Directives in Europe
Table 21.8 Conformity Assessment Modules in Europe
Table 21.9 Device Classification: Australia
Table 21.10 Medical Devices Reimbursement and Pricing Approval Process: Australia
Table 21.11 Device Classification: Brazil
Table 21.12 Device Classification: China
Table 21.13 Device Classification: India
Table 21.14 Device Classification: Japan
Table 21.15 Medical Devices Reimbursement Categories
Table 21.16 Device Classification: Medsafe
Table 21.17 Device Classification: Singapore
Table 21.18 Device Classification: South Korea
Table 21.19 Device Classification: South Africa
Table 21.20 Device Classification: Thailand
Table 21.21 Medical Devices Regulatory Landscape Summary
Table 21.22 Medical Devices Reimbursement Landscape Summary
Table 25.1 Company Snapshot: Company A
Table 25.2 Company Snapshot: Company B
Table 25.3 Company Snapshot: Company C
Table 25.4 Company Snapshot: Company D
Table 25.5 Company Snapshot: Company E
Table 25.6 Company Snapshot: Company F
Table 25.7 Company Snapshot: Company G
Table 25.8 Company Snapshot: Company H
Table 25.9 Company Snapshot: Company I
Table 25.10 Company Snapshot: Company J
Table 34.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 34.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Table 34.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 34.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Table 34.18 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Table 34.19 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Table 34.20 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Table 34.21 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Table 34.22 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Table 34.23 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Table 34.24 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Table 34.25 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Table 34.26 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Table 34.27 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 34.28 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Table 34.29 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Table 34.30 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Table 34.31 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Table 34.32 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.33 Device Developers: Distribution by Number of Drug Device Combination Developed
Table 34.34 Wearable Injectors for Insulin: Distribution by Type of Device
Table 34.35 Wearable Injectors for Insulin: Distribution by Status of Development
Table 34.36 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Table 34.37 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Table 34.38 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Table 34.39 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Table 34.40 Wearable Injectors for Insulin: Distribution by Usability
Table 34.41 Wearable Injectors for Insulin: Distribution by Period of Use
Table 34.42 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Table 34.43 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Table 34.44 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Table 34.45 Wearable Injectors for Insulin: Distribution by Type of Dose
Table 34.46 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Table 34.47 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Table 34.48 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Table 34.49 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Table 34.50 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Table 34.51 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Table 34.52 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Table 34.53 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Table 34.54 Product Competitiveness Analysis: Wearable Injectors for Insulin
Table 34.55 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Table 34.56 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.57 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.58 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Table 34.59 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Table 34.60 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Table 34.61 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 34.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 34.63 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Table 34.64 Partnerships and Collaborations: Distribution by Partner
Table 34.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 34.66 Partnerships and Collaborations: Distribution by Type of Device
Table 34.67 Most Active Players: Distribution by Number of Partnerships
Table 34.68 Most Active Players: Distribution by Type of Partnership
Table 34.69 Partnerships and Collaborations: Local and International Agreements
Table 34.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 34.71 Patent Analysis: Distribution by Type of Patent
Table 34.72 Patent Analysis: Distribution by Patent Publication Year
Table 34.73 Patent Analysis: Distribution by Patent Application Year
Table 34.74 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Table 34.75 Patent Analysis: Distribution by Jurisdiction
Table 34.76 Patent Analysis: Distribution by Type of Applicant
Table 34.77 Leading Industry Players: Distribution by Number of Patents
Table 34.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 34.79 Leading Individual Assignees: Distribution by Number of Patents
Table 34.80 Patent Analysis: Distribution by Patent Age
Table 34.81 Wearable Injectors: Patent Valuation
Table 34.82 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 34.83 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 34.84 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 34.85 Clinical Trial Analysis: Distribution by Trial Phase
Table 34.86 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 34.87 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 34.88 Clinical Trial Analysis: Distribution by Study Design
Table 34.89 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 34.90 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 34.91 Most Active Players: Distribution by Number of Registered Trials
Table 34.92 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Table 34.93 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 34.94 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Table 34.95 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Table 34.96 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Table 34.97 Funding and Investment Analysis: Distribution by Type of Funding
Table 34.98 Funding and Investment Analysis: Distribution by Type of Device
Table 34.99 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Table 34.100 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 34.101 Most Active Players: Distribution by Number of Funding Instances
Table 34.102 Most Active Players: Distribution by Amount Invested
Table 34.103 Leading Investors: Distribution by Number of Funding Instances
Table 34.104 Funding and Investments: Distribution by Geography
Table 34.105 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.106 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.107 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Table 34.108 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.109 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.110 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Table 34.111 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.112 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.113 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Table 34.114 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.115 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.116 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Table 34.117 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.118 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.119 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Table 34.120 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.121 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.122 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.123 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.124 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.125 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Table 34.126 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.127 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.128 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.129 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.130 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.131 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Table 34.132 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.133 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.134 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.135 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.136 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.137 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Table 34.138 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.139 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.140 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.141 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.142 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.143 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.144 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.145 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Table 34.146 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.147 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.148 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Table 34.149 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.150 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.151 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Table 34.152 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.153 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.154 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Table 34.155 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.156 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.157 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Table 34.158 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.159 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.160 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.161 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.162 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.163 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.164 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.165 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.166 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.167 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.168 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.169 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.170 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.171 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.172 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.173 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.174 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.175 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.176 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.177 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.178 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.179 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.180 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.181 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Table 34.182 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Table 34.183 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.184 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.185 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.186 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.187 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.188 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.189 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.190 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.191 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.192 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.193 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.194 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.195 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.196 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.197 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.198 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.199 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.200 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.201 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.202 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Table 34.203 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Drug Delivery Systems
Figure 6.2 Evolution of Healthcare Safety Legislations
Figure 6.3 Wearable Injectors Market: Key Driving Factors
Figure 6.4 Types of Self-Injection Devices
Figure 7.1 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 7.2 Wearable Injectors for Non-Insulin Drugs: Distribution by Status of Development
Figure 7.3 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.4 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 7.5 Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 7.6 Wearable Injectors for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 7.7 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 7.8 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 7.9 Wearable Injectors for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 7.10 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 7.11 Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 7.12 Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 7.13 Wearable Injectors for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 7.14 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 7.15 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Company Size
Figure 7.16 Wearable Injectors for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 7.17 Leading Players: Distribution by Number of Wearable Injectors Developed for Non-Insulin
Figure 8.1 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Device
Figure 8.2 Drug Device Combinations for Non-Insulin Drugs: Distribution by Status of Development
Figure 8.3 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Delivery
Figure 8.4 Drug Device Combinations for Non-Insulin Drugs: Distribution by Usability
Figure 8.5 Drug Device Combinations for Non-Insulin Drugs: Distribution by Drug Reservoir Volume
Figure 8.6 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Molecule
Figure 8.7 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Dose
Figure 8.8 Drug Device Combinations for Non-Insulin Drugs: Distribution by Dose of Drug
Figure 8.9 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Injection
Figure 8.10 Drug Device Combinations for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 8.11 Drug Device Combinations for Non-Insulin Drugs: Distribution by Type of Drug Container
Figure 8.12 Drug Device Combinations for Non-Insulin Drugs: Distribution by Mode of Drug Filling
Figure 8.13 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Year of Establishment
Figure 8.14 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Company Size
Figure 8.15 Drug Device Combinations for Non-Insulin Drug Developers: Distribution by Location of Headquarters
Figure 8.16 Device Developers: Distribution by Number of Drug Device Combination Developed
Figure 9.1 Wearable Injectors for Insulin: Distribution by Type of Device
Figure 9.2 Wearable Injectors for Insulin: Distribution by Status of Development
Figure 9.3 Wearable Injectors for Insulin: Distribution by Type of Insulin Delivery
Figure 9.4 Wearable Injectors for Insulin: Distribution by Type of Automated Insulin Delivery
Figure 9.5 Wearable Injectors for Insulin: Distribution by Type of Connectivity Feature
Figure 9.6 Wearable Injectors for Insulin: Distribution by Waterproof Capability
Figure 9.7 Wearable Injectors for Insulin: Distribution by Usability
Figure 9.8 Wearable Injectors for Insulin: Distribution by Period of Use
Figure 9.9 Wearable Injectors for Insulin: Distribution by Type of Advanced Feature
Figure 9.10 Wearable Injectors for Insulin: Distribution by Type of Drug Container
Figure 9.11 Wearable Injectors for Insulin: Distribution by Mode of Drug Filling
Figure 9.12 Wearable Injectors for Insulin: Distribution by Type of Dose
Figure 9.13 Wearable Injectors for Insulin: Distribution by Type of Diabetes
Figure 9.14 Wearable Injectors for Insulin: Distribution by Availability of Connectivity Feature
Figure 9.15 Wearable Injectors for Insulin Drug Developers: Distribution by Year of Establishment
Figure 9.16 Wearable Injectors for Insulin Drug Developers: Distribution by Company Size
Figure 9.17 Wearable Injectors for Insulin Drug Developers: Distribution by Location of Headquarters
Figure 9.18 Leading Players: Distribution by Number of Wearable Injectors for Insulin
Figure 10.1 Product Competitiveness Analysis: Wearable Injectors for Non-Insulin Drugs
Figure 10.2 Product Competitiveness Analysis: Drug Device Combinations for Non-Insulin Drugs
Figure 10.3 Product Competitiveness Analysis: Wearable Injectors for Insulin
Figure 11.1 Gerresheimer: Annual Revenues, FY 2022 Onwards (EUR Million)
Figure 11.2 West Pharmaceuticals: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.3 Eli Lilly: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.4 Insulet: Annual Revenues, FY 2022 Onwards (USD Million)
Figure 11.5 Medtronic: Annual Revenues, FY 2022 Onwards (USD Billion)
Figure 11.6 Roche: Annual Revenues, FY 2022 Onwards (CHF Billion)
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2015
Figure 13.4 Partnerships and Collaborations: Distribution by Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 13.6 Partnerships and Collaborations: Distribution by Type of Device
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Most Active Players: Distribution by Type of Partnership
Figure 13.9 Partnerships and Collaborations: Local and International Agreements
Figure 13.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Distribution by Patent Publication Year
Figure 15.3 Patent Analysis: Distribution by Patent Application Year
Figure 15.4 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year
Figure 15.5 Patent Analysis: Distribution by Jurisdiction
Figure 15.6 Patent Analysis: Distribution by Type of Applicant
Figure 15.7 Patent Analysis: Distribution by CPC Symbols
Figure 15.8 Leading Industry Players: Distribution by Number of Patents
Figure 15.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 15.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 15.11 Patent Benchmarking: Distribution by Patent Characteristics (CPC Symbols)
Figure 15.12 Patent Analysis: Distribution by Patent Age
Figure 15.13 Wearable Injectors: Patent Valuation
Figure 17.1 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 17.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 17.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 17.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 17.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 17.6 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 17.7 Clinical Trial Analysis: Distribution by Study Design
Figure 17.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 17.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 17.10 Most Active Players: Distribution by Number of Registered Trials
Figure 17.11 Most Popular Wearable Injectors: Distribution by Number of Registered Trials
Figure 17.12 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 17.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Figure 18.1 Funding and Investment Analysis: Distribution of Year of Funding, Since 2014
Figure 18.2 Funding and Investment Analysis: Distribution of Amount Invested by Year, Since 2014 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution by Type of Device
Figure 18.5 Funding and Investment Analysis: Year-wise Distribution by Type of Funding and Amount Raised (USD Million)
Figure 18.6 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 18.7 Most Active Players: Distribution by Number of Funding Instances
Figure 18.8 Most Active Players: Distribution by Amount Invested
Figure 18.9 Leading Investors: Distribution by Number of Funding Instances
Figure 18.10 Funding and Investments: Distribution by Geography
Figure 19.1 SWOT Factors: Harvey Ball Analysis
Figure 20.1 CMOs: Distribution by Geography
Figure 21.1 Key Regulatory Authorities for Medical Devices
Figure 21.2 Medical Devices Review / Approval Process in the US
Figure 21.3 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 21.4 Medical Devices National Coverage Determination Process: US
Figure 21.5 Medical Devices Review / Approval Process in Canada
Figure 21.6 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 21.7 Medical Devices Review / Approval Process in Mexico
Figure 21.8 Regulatory Bodies in EU5 Countries
Figure 21.9 Steps involved in CE Marking Process
Figure 21.10 Medical Devices Review / Approval Process in Europe
Figure 21.11 Medical Devices Review / Approval Process in the UK
Figure 21.12 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 21.13 Medical Devices Reimbursement Process: UK
Figure 21.14 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 21.15 Medical Devices Reimbursement Process: France
Figure 21.16 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 21.17 Medical Devices Reimbursement Process for In-Patient Setting: Germany
Figure 21.18 Medical Devices Reimbursement Process for Out-Patient Care: Germany
Figure 21.19 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Figure 21.20 Medical Devices Reimbursement Process: Italy
Figure 21.21 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 21.22 Medical Devices Reimbursement Process: Spain
Figure 21.23 Medical Devices Review / Approval Process in Australia
Figure 21.24 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 21.25 Medical Devices Review / Approval Process in Brazil
Figure 21.26 Medical Devices Reimbursement Process: Brazil
Figure 21.27 Medical Devices Review / Approval Process in China
Figure 21.28 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 21.29 Medical Devices Reimbursement Process: Shanghai
Figure 21.30 Medical Devices Review / Approval Process in India
Figure 21.31 Healthcare Insurance Coverage in Israel: Distribution by Type of Coverage
Figure 21.32 Medical Devices Review / Approval Process in Japan
Figure 21.33 Medical Devices Reimbursement Process: Japan
Figure 21.34 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 21.35 New Medical Devices Reimbursement Process: Japan
Figure 21.36 Medical Devices Review / Approval Process in New Zealand
Figure 21.37 Healthcare Insurance Coverage in New Zealand: Distribution by Type of Coverage
Figure 21.38 Medical Devices Review / Approval Process in Singapore
Figure 21.39 Medical Devices Review / Approval Process in South Korea
Figure 21.40 Healthcare Insurance Coverage in South Korea: Distribution by Type of Coverage
Figure 21.41 Medical Devices Review / Approval Process in South Africa
Figure 21.42 Medical Devices Review / Approval Process in Taiwan
Figure 21.43 Healthcare Insurance Coverage in Taiwan: Distribution by Type of Coverage
Figure 21.44 Medical Devices Review / Approval Process in Thailand
Figure 21.45 Heat Map Analysis: Comparison of Regional Regulatory Guidelines for Medical Devices
Figure 21.46 Regulatory Control for Medical Devices: Regional Analysis by Device Risk Category
Figure 23.1 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 23.2 Global Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Value)
Figure 24.2 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.3 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 24.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device (By Volume)
Figure 24.5 Wearable Patch Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 24.6 Wearable Infusion Pump Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Value)
Figure 25.2 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.3 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 25.4 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability (By Volume)
Figure 25.5 Disposable Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 25.6 Reusable / Disposable Components Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Value)
Figure 26.2 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.3 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.4 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.5 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.6 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 26.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area (By Volume)
Figure 26.8 Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.9 Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.10 Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.11 Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 26.12 Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.1 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Value)
Figure 27.2 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.3 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.4 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.5 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.6 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 27.7 Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geographical Regions (By Volume)
Figure 27.8 Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.9 Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.10 Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.11 Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.12 Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 27.13 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 27.14 Market Movement Analysis: Geographical Regions
Figure 28.1 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 28.2 Global Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.1 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Value)
Figure 29.2 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.3 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 29.4 Wearable Injectors Market for Insulin: Distribution by Type of Device (By Volume)
Figure 29.5 Wearable Patch Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 29.6 Wearable Infusion Pump Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.1 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Value)
Figure 30.2 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.3 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 30.4 Wearable Injectors Market for Insulin: Distribution by Degree of Automation (By Volume)
Figure 30.5 Automated / Smart Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 30.6 Manual Wearable Injectors Market for Insulin, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.1 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Value)
Figure 31.2 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.3 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.4 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.5 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.6 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.7 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.8 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.9 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.10 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.11 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.12 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.13 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.14 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.15 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.16 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.17 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.18 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.19 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.20 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.21 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.22 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.23 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.24 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.25 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Value)
Figure 31.26 Wearable Injectors Market for Insulin: Distribution by Geographical Regions (By Volume)
Figure 31.27 Wearable Injectors Market for Insulin in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.28 Wearable Injectors Market for Insulin in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.29 Wearable Injectors Market for Insulin in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.30 Wearable Injectors Market for Insulin in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.31 Wearable Injectors Market for Insulin in Germany, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.32 Wearable Injectors Market for Insulin in the UK, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.33 Wearable Injectors Market for Insulin in Spain, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.34 Wearable Injectors Market for Insulin in France, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.35 Wearable Injectors Market for Insulin in Italy, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.36 Wearable Injectors Market for Insulin in Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.37 Wearable Injectors Market for Insulin in Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.38 Wearable Injectors Market for Insulin in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.39 Wearable Injectors Market for Insulin in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.40 Wearable Injectors Market for Insulin in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.41 Wearable Injectors Market for Insulin in Pakistan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.42 Wearable Injectors Market for Insulin in Rest of Asia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.43 Wearable Injectors Market for Insulin in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.44 Wearable Injectors Market for Insulin in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.45 Wearable Injectors Market for Insulin in Mexico, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.46 Wearable Injectors Market for Insulin in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.47 Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.48 Wearable Injectors Market for Insulin in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.49 Wearable Injectors Market for Insulin in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.50 Wearable Injectors Market for Insulin in Egypt, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (By Volume)
Figure 31.51 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 31.52 Market Movement Analysis: Geographical Regions
Figure 32.1 Concluding Remarks: Market Landscape of Wearable Injectors for Non-Insulin
Figure 32.2 Concluding Remarks: Market Landscape of Drug Device Combinations
Figure 32.3 Concluding Remarks: Market Landscape of Wearable Injectors for Insulin
Figure 32.4 Concluding Remarks: Partnerships and Collaborations
Figure 32.5 Concluding Remarks: Key Acquisition Targets
Figure 32.6 Concluding Remarks: Patent Analysis
Figure 32.7 Concluding Remarks: Likely Drug Candidates
Figure 32.8 Concluding Remarks: Clinical Trial Analysis
Figure 32.9 Concluding Remarks: Funding and Investment Analysis
Figure 32.10 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Non-Insulin
Figure 32.11 Concluding Remarks: Market Sizing and Opportunity Analysis for Wearable Injectors for Insulinsis
提及公司
同分類最新報告（醫療器材）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們